Therapeutic effect of intravesical administration of paclitaxel solubilized with poly(2-methacryloyloxyethyl phosphorylcholine-co-n-butyl methacrylate) in an orthotopic bladder cancer model

[1] Kikuchi E(2009)Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association Int J Urol 16 279-86

[2] Fujimoto H(2013)Diagnosis of narrow-band imaging in non-muscle-invasive bladder cancer: a systematic review and meta-analysis Int J Urol 20 602-9

[3] Mizutani Y(2000)Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study J Urol 163 1124-9

[4] Okajima E(2003)Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity J Urol 169 90-5

[5] Koga H(2009)An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guerin for non-muscle-invasive bladder cancer Eur Urol 56 247-56

[6] Hinotsu S(2010)Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guerin, and bacillus Calmette-Guerin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder Eur Urol 57 766-73

[7] Li K(2009)Discontinuance of bacille Calmette-Guerin instillation therapy for nonmuscle-invasive bladder cancer has negative effect on tumor recurrence Urology 73 1318-22

[8] Lin T(2000)Treatment of superficial bladder tumors: achievements and needs. The EORTC Genitourinary Group Eur Urol 37 1-9

[9] Fan X(1993)Penetration of mitomycin C in human bladder Cancer Res 53 3314-20

[10] Duan Y(1996)Penetration of intravesical doxorubicin in human bladders Cancer Chemother Pharmacol 37 539-46

[1] Kikuchi E(2009)Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association Int J Urol 16 279-86

[2] Fujimoto H(2013)Diagnosis of narrow-band imaging in non-muscle-invasive bladder cancer: a systematic review and meta-analysis Int J Urol 20 602-9

[3] Mizutani Y(2000)Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study J Urol 163 1124-9

[4] Okajima E(2003)Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity J Urol 169 90-5

[5] Koga H(2009)An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guerin for non-muscle-invasive bladder cancer Eur Urol 56 247-56

[6] Hinotsu S(2010)Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guerin, and bacillus Calmette-Guerin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder Eur Urol 57 766-73

[7] Li K(2009)Discontinuance of bacille Calmette-Guerin instillation therapy for nonmuscle-invasive bladder cancer has negative effect on tumor recurrence Urology 73 1318-22

[8] Lin T(2000)Treatment of superficial bladder tumors: achievements and needs. The EORTC Genitourinary Group Eur Urol 37 1-9

[9] Fan X(1993)Penetration of mitomycin C in human bladder Cancer Res 53 3314-20

[10] Duan Y(1996)Penetration of intravesical doxorubicin in human bladders Cancer Chemother Pharmacol 37 539-46